News stories about Oramed Pharmaceuticals (NASDAQ:ORMP) have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Oramed Pharmaceuticals earned a daily sentiment score of 0.04 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 44.7939771127576 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Separately, HC Wainwright set a $25.00 price objective on shares of Oramed Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, May 22nd.
Shares of Oramed Pharmaceuticals (NASDAQ:ORMP) traded down 0.61% during trading on Friday, reaching $8.11. The company’s stock had a trading volume of 11,521 shares. The stock’s 50 day moving average price is $8.17 and its 200 day moving average price is $7.27. Oramed Pharmaceuticals has a 52 week low of $5.70 and a 52 week high of $9.17. The company’s market cap is $108.03 million.
In related news, Director Xiaopeng Li acquired 89,636 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The shares were bought at an average price of $8.50 per share, for a total transaction of $761,906.00. Following the purchase, the director now directly owns 206,350 shares in the company, valued at approximately $1,753,975. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 27.50% of the company’s stock.
WARNING: This piece was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://stocknewstimes.com/2017/08/20/oramed-pharmaceuticals-ormp-getting-somewhat-positive-media-coverage-analysis-finds.html.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.
Receive News & Ratings for Oramed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
